Cadila Healthcare today said the US health regulator has issued five observations after inspection of its subsidiary Liva Pharmaceuticals' injectables manufacturing facility.
"This was a product specific pre-approval inspection. It concluded with 5 observations. Liva will respond to USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market," Cadila Healthcare said in a filing to BSE.
The injectables facility is located at Vadodara.
United States Food and Drug Administration (USFDA) conducted the inspection from August 20-28. Liva is a 100 per cent subsidiary of Cadila Healthcare.
Shares of Cadila Healthcare were trading 1.78 per cent lower at Rs 389.40 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
